Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)

  • Motas, Sandra|||0000-0003-2748-5952
  • Haurigot Mendonça, Virginia|||0000-0002-9772-2565
  • Garcia, Miquel|||0000-0002-1602-4993
  • Marcó, Sara|||0000-0003-3502-5198
  • Ribera Sánchez, Albert|||0000-0002-7120-4276
  • Roca Lecha, Carles|||0000-0002-3744-3089
  • Sanchez Moreno, Xavier|||0000-0003-0897-0661
  • Sánchez Clares, Víctor|||0000-0001-8631-9239
  • Molas, Maria
  • Bertolín Gálvez, Joan|||0000-0002-5196-0955
  • Maggioni, Luca
  • León, Xavier|||0000-0002-8393-2721
  • Ruberte Paris, Jesús|||0000-0003-1540-1432
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
Mucopolysaccharidosis type II (MPSII) is an X-linked lysosomal storage disease characterized by severe neurologic and somatic disease caused by deficiency of iduronate-2-sulfatase (IDS), an enzyme that catabolizes the glycosaminoglycans heparan and dermatan sulphate. Intravenous enzyme replacement therapy (ERT) currently constitutes the only approved therapeutic option for MPSII. However, the inability of recombinant IDS to efficiently cross the blood-brain barrier (BBB) limits ERT efficacy in treating neurological symptoms. Here, we report a gene therapy approach for MPSII through direct delivery of vectors to the CNS. Through a minimally invasive procedure, we administered adeno-associated virus vectors encoding IDS (AAV9-Ids) to the cerebrospinal fluid of MPSII mice with already established disease. Treated mice showed a significant increase in IDS activity throughout the encephalon, with full resolution of lysosomal storage lesions, reversal of lysosomal dysfunction, normalization of brain transcriptomic signature, and disappearance of neuroinflammation. Moreover, our vector also transduced the liver, providing a peripheral source of therapeutic protein that corrected storage pathology in visceral organs, with evidence of cross-correction of nontransduced organs by circulating enzyme. Importantly, AAV9-Ids-treated MPSII mice showed normalization of behavioral deficits and considerably prolonged survival. These results provide a strong proof of concept for the clinical translation of our approach for the treatment of Hunter syndrome patients with cognitive impairment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

2 sustains thermogenesis via Akt-induced glucose uptake and glycolysis in brown adipose tissue

  • Albert, Verena
  • Svensson, Kristoffer
  • Shimobayashi, Mitsugu
  • Colombi, Marco
  • Muñoz-Martínez, S|||0000-0003-0663-0575
  • Jimenez, Veronica|||0000-0001-9145-9877
  • Handschin, Christoph
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
  • Hall, Michael N.|||0000-0002-2998-0757
Activation of non-shivering thermogenesis () in brown adipose tissue () has been proposed as an anti-obesity treatment. Moreover, cold-induced glucose uptake could normalize blood glucose levels in insulin-resistant patients. It is therefore important to identify novel regulators of and cold-induced glucose uptake. Mammalian target of rapamycin complex 2 (2) mediates insulin-stimulated glucose uptake in metabolic tissues, but its role in is unknown. We show that 2 is activated in brown adipocytes upon β-adrenergic stimulation. Furthermore, mice lacking 2 specifically in adipose tissue (AdRi mice) are hypothermic, display increased sensitivity to cold, and show impaired cold-induced glucose uptake and glycolysis. Restoration of glucose uptake in by overexpression of hexokinase or activated Akt2 was sufficient to increase body temperature and improve cold tolerance in AdRi mice. Thus, 2 in mediates temperature homeostasis via regulation of cold-induced glucose uptake. Our findings demonstrate the importance of glucose metabolism in temperature regulation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Progressive neurologic and somatic disease in a novel mouse model of human mucopolysaccharidosis type IIIC

  • Marcó, Sara|||0000-0003-3502-5198
  • Pujol i Altarriba, Anna|||0000-0002-3484-598X
  • Roca Lecha, Carles|||0000-0002-3744-3089
  • Motas, Sandra|||0000-0003-2748-5952
  • Ribera Sánchez, Albert|||0000-0002-7120-4276
  • Garcia, Miquel|||0000-0002-1602-4993
  • Molas, Maria
  • Villacampa, Pilar|||0000-0002-2860-7475
  • Melia, Cristian S.
  • Sánchez Clares, Víctor|||0000-0001-8631-9239
  • Sanchez Moreno, Xavier|||0000-0003-0897-0661
  • Bertolín Gálvez, Joan|||0000-0002-5196-0955
  • Ruberte Paris, Jesús|||0000-0003-1540-1432
  • Haurigot Mendonça, Virginia|||0000-0002-9772-2565
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
Mucopolysaccharidosis type IIIC (MPSIIIC) is a severe lysosomal storage disease caused by deficiency in activity of the transmembrane enzyme heparan-α-glucosaminide N-acetyltransferase (HGSNAT) that catalyses the N-acetylation of α-glucosamine residues of heparan sulfate. Enzyme deficiency causes abnormal substrate accumulation in lysosomes, leading to progressive and severe neurodegeneration, somatic pathology and early death. There is no cure for MPSIIIC, and development of new therapies is challenging because of the unfeasibility of cross-correction. In this study, we generated a new mouse model of MPSIIIC by targeted disruption of the Hgsnat gene. Successful targeting left LacZ expression under control of the Hgsnat promoter, allowing investigation into sites of endogenous expression, which was particularly prominent in the CNS, but was also detectable in peripheral organs. Signs of CNS storage pathology, including glycosaminoglycan accumulation, lysosomal distension, lysosomal dysfunction and neuroinflammation were detected in 2-month-old animals and progressed with age. Glycosaminoglycan accumulation and ultrastructural changes were also observed in most somatic organs, but lysosomal pathology seemed most severe in liver. Furthermore, HGSNAT-deficient mice had altered locomotor and exploratory activity and shortened lifespan. Hence, this animal model recapitulates human MPSIIIC and provides a useful tool for the study of disease physiopathology and the development of new therapeutic approaches. Summary: A new animal model of the severe neurodegenerative lysosomal disorder mucopolysaccharidosis IIIC recapitulates the human disease, with progressive CNS and somatic lysosomal pathology, and shortened lifespan.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

BMP7 overexpression in adipose tissue induces white adipogenesis and improves insulin sensitivity in ob/ob mice

  • Casaña Lorente, Estefania|||0000-0002-1353-5018
  • Jimenez, Veronica|||0000-0001-9145-9877
  • Sacristan, Victor|||0000-0003-0356-0356
  • Muñoz-Martínez, S|||0000-0003-0663-0575
  • Jambrina Pallarés, Claudia
  • Rodó Morera, Jordi|||0000-0001-8533-2597
  • Garcia, Miquel|||0000-0002-1602-4993
  • Mallol, Cristina|||0000-0002-2920-9612
  • León, Xavier|||0000-0002-8393-2721
  • Franckhauser, Sylvie|||0000-0001-5255-1224
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
Background/objectives: During obesity, hypertrophic enlargement of white adipose tissue (WAT) promotes ectopic lipid deposition and development of insulin resistance. In contrast, WAT hyperplasia is associated with preservation of insulin sensitivity. The complex network of factors that regulates white adipogenesis is not fully understood. Bone morphogenic protein 7 (BMP7) can induce brown adipogenesis, but its role on white adipogenesis remains to be elucidated. Here, we assessed BMP7-mediated effects on white adipogenesis in ob/ob mice. Methods: BMP7 was overexpressed in either WAT or liver of ob/ob mice using adeno-associated viral (AAV) vectors. Analysis of gene expression, histological and morphometric alterations, and metabolites and hormones concentrations were carried out. Results: Overexpression of BMP7 in adipocytes of subcutaneous and visceral WAT increased fat mass, the proportion of small-size adipocytes and the expression of adipogenic and mature adipocyte genes, suggesting induction of adipogenesis irrespective of fat depot. These changes were associated with reduced hepatic steatosis and improved insulin sensitivity. In contrast, liver-specific overproduction of BMP7 did not promote WAT hyperplasia despite BMP7 circulating levels were similar to those achieved after genetic engineering of WAT. Conclusions: This study unravels a new autocrine/paracrine role of BMP7 on white adipogenesis and highlights that BMP7 may modulate WAT plasticity and increase insulin sensitivity.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

FGF21 gene therapy as treatment for obesity and insulin resistance

  • Jimenez, Veronica|||0000-0001-9145-9877
  • Jambrina Pallarés, Claudia|||0000-0002-9093-5568
  • Casaña Lorente, Estefania|||0000-0002-1353-5018
  • Sacristan, Victor|||0000-0003-0356-0356
  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Darriba, Sara
  • Rodó Morera, Jordi|||0000-0001-8533-2597
  • Mallol, Cristina|||0000-0002-2920-9612
  • Garcia, Miquel|||0000-0002-1602-4993
  • León, Xavier|||0000-0002-8393-2721
  • Marcó, Sara|||0000-0003-3502-5198
  • Ribera Sánchez, Albert|||0000-0002-7120-4276
  • Elias Puigdomenech, Ivet|||0000-0002-1304-9597
  • Casellas Comallonga, Alba|||0000-0003-0203-4733
  • Grass Costa, Ignasi|||0000-0002-6917-3271
  • Elias Bosch, Gemma|||0000-0003-1985-7955
  • Ferre, Tura|||0000-0001-9713-0829
  • Motas, Sandra|||0000-0003-2748-5952
  • Franckhauser, Sylvie|||0000-0001-5255-1224
  • Mulero, Francisca|||0000-0001-9584-4211
  • Navarro Beltrán, Marc|||0000-0002-9678-6129
  • Haurigot Mendonça, Virginia|||0000-0002-9772-2565
  • Ruberte Paris, Jesús|||0000-0003-1540-1432
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
Prevalence of type 2 diabetes (T2D) and obesity is increasing worldwide. Currently available therapies are not suited for all patients in the heterogeneous obese/T2D population, hence the need for novel treatments. Fibroblast growth factor 21 (21) is considered a promising therapeutic agent for T2D/obesity. Native 21 has, however, poor pharmacokinetic properties, making gene therapy an attractive strategy to achieve sustained circulating levels of this protein. Here, adeno-associated viral vectors () were used to genetically engineer liver, adipose tissue, or skeletal muscle to secrete 21. Treatment of animals under long-term high-fat diet feeding or of ob/ob mice resulted in marked reductions in body weight, adipose tissue hypertrophy and inflammation, hepatic steatosis, inflammation and fibrosis, and insulin resistance for.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Identification of miRNAs Involved in Reprogramming Acinar Cells into Insulin Producing Cells

  • Teichenne, Joan|||0000-0002-3455-5923
  • Morró Larrubia, Meritxell|||0000-0003-1725-9599
  • Casellas, Alba|||0000-0003-0203-4733
  • Jimenez, Veronica|||0000-0001-9145-9877
  • Tellez, Noelia
  • Leger, Adrien
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
  • Ayuso, Eduard|||0000-0003-0811-2229
Reprogramming acinar cells into insulin producing cells using adenoviral (Ad)-mediated delivery of Pdx1, Ngn3 and MafA (PNM) is an innovative approach for the treatment of diabetes. Here, we aimed to investigate the molecular mechanisms involved in this process and in particular, the role of microRNAs. To this end, we performed a comparative study of acinar-to-β cell reprogramming efficiency in the rat acinar cell line AR42J and its subclone B13 after transduction with Ad-PNM. B13 cells were more efficiently reprogrammed than AR42J cells, which was demonstrated by a strong activation of β cell markers (Ins1, Ins2, IAPP, NeuroD1 and Pax4). miRNome panels were used to analyze differentially expressed miRNAs in acinar cells under four experimental conditions (i) non-transduced AR42J cells, (ii) non-transduced B13 cells, (iii) B13 cells transduced with Ad-GFP vectors and (iv) B13 cells transduced with Ad-PNM vectors. A total of 59 miRNAs were found to be differentially expressed between non-transduced AR42J and B13 cells. Specifically, the miR-200 family was completely repressed in B13 cells, suggesting that these cells exist in a less differentiated state than AR42J cells and as a consequence they present a greater plasticity. Adenoviral transduction per se induced dedifferentiation of acinar cells and 11 miRNAs were putatively involved in this process, whereas 8 miRNAs were found to be associated with PNM expression. Of note, Ad-PNM reprogrammed B13 cells presented the same levels of miR-137-3p, miR-135a-5p, miR-204-5p and miR-210-3p of those detected in islets, highlighting their role in the process. In conclusion, this study led to the identification of miRNAs that might be of compelling importance to improve acinar-to-β cell conversion for the future treatment of diabetes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Biochemical, histological and functional correction of mucopolysaccharidosis Type IIIB by intra-cerebrospinal fluid gene therapy

  • Ribera Sánchez, Albert|||0000-0002-7120-4276
  • Haurigot Mendonça, Virginia|||0000-0002-9772-2565
  • Garcia, Miquel|||0000-0002-1602-4993
  • Marcó, Sara|||0000-0003-3502-5198
  • Motas, Sandra|||0000-0003-2748-5952
  • Villacampa, Pilar|||0000-0002-2860-7475
  • Maggioni, Luca
  • León, Xavier|||0000-0002-8393-2721
  • Molas Laplana, Maria|||0000-0002-3215-515X
  • Sánchez Clares, Víctor|||0000-0001-8631-9239
  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Leborgne, Christian
  • Moll, Xavier|||0000-0002-2992-9361
  • Pumarola i Batlle, Martí|||0000-0002-0935-7941
  • Mingozzi, Federico
  • Ruberte Paris, Jesús|||0000-0003-1540-1432
  • Añor Torres, Sònia|||0000-0002-1099-7698
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
Gene therapy is an attractive tool for the treatment of monogenic disorders, in particular for lysosomal storage diseases (LSD) caused by deficiencies in secretable lysosomal enzymes in which neither full restoration of normal enzymatic activity nor transduction of all affected cells are necessary. However, some LSD such as Mucopolysaccharidosis Type IIIB (MPSIIIB) are challenging because the disease's main target organ is the brain and enzymes do not efficiently cross the blood-brain barrier even if present at very high concentration in circulation. To overcome these limitations,we delivered AAV9 vectors encoding for α-N-acetylglucosaminidase (NAGLU) to the Cerebrospinal Fluid (CSF) of MPSIIIB mice with the disease already detectable at biochemical, histological and functional level. Restoration of enzymatic activity in Central Nervous System (CNS) resulted in normalization of glycosaminoglycan content and lysosomal physiology, resolved neuroinflammation and restored the pattern of gene expression in brain similar to that of healthy animals. Additionally, transduction of the liver due to passage of vectors to the circulation led to whole-body disease correction. Treated animals also showed reversal of behavioural deficits and extended lifespan. Importantly, when the levels of enzymatic activity were monitored in the CSF of dogs following administration of canine NAGLU-coding vectors to animals that were either naïve or had pre-existing immunity against AAV9, similar levels of activity were achieved, suggesting that CNS efficacy would not be compromised in patients seropositive for AAV9. Our studies provide a strong rationale for the clinical development of this novel therapeutic approach as the treatment for MPSIIIB.